Figshareopen access
First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data
medicine, pharmacology, biotechnology, sociology, cancer, science policy, biological sciences not elsewhere classified, cost-effectiveness
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 458447
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.